Dubois Luc, McClure J Andrew, Vogt Kelly, Welk Blayne, Clarke Collin
Department of Surgery, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada; London Health Sciences Centre, London, Ontario, Canada; ICES Western, London, Ontario, Canada.
London Health Sciences Centre, London, Ontario, Canada; ICES Western, London, Ontario, Canada.
Ann Vasc Surg. 2024 Jan;98:274-281. doi: 10.1016/j.avsg.2023.08.008. Epub 2023 Oct 5.
Few studies have looked at the long-term risk of opioid use following major vascular surgery and no study has investigated the potential association between major complications and prolonged opioid use. We analyzed a population-based database linked to a prescription database to investigate factors associated with prolonged opioid use following major vascular surgery.
This population-based cohort study included all adults who underwent open lower extremity revascularization (LER) or nonruptured abdominal aortic aneurysm repair (open [AAA] and endovascular [EVAR]) in the province of Ontario, Canada, between 2013 and 2018. Prolonged opioid use was defined as 2 or more opioid prescriptions filled 6-12 months following surgery. Potential predictors of prolonged use were explored using modified Poisson regression with a generalized estimating equation approach to account for the clustering of patients within physicians and institutions.
This study included a total of 11,104 patients with 5,652 patients undergoing open LER, 3,285 patients undergoing EVAR, and 2,167 patients undergoing AAA. The rates of prior opioid use were 35.4% for LER, 15.8% for AAA and 14.3% for EVAR. Major complication rates following each procedure were 59.5% for AAA, 35.1% for LER, and 21.0% for EVAR. Following surgery, prolonged opioid use was identified in 26.1% of LER, 13.2% of AAA, and 11.6% of EVAR patients. The strongest predictor of prolonged opioid use was prior use with an odds ratio (OR) of 13.27 (95% CI: 10.63-16.57) for AAA, 11.24 (95% CI: 9.18-13.75) for EVAR, and 4.69 (95% CI: 4.16-5.29) for LER. The occurrence of a major complication was only associated with prolonged opioid use for patients undergoing LER (OR 1.10; 95% CI: 1.03-1.19), while it had a protective effect on patients undergoing EVAR (OR 0.83; 95% CI: 0.69-0.99) and no association for patients undergoing open AAA repair (OR 1.11; 95% CI: 0.95-1.29). Older age was also protective with a reduced rate of prolonged opioid use for every 10 years of age increase: AAA (OR 0.87; 95% CI: 0.77-0.99); EVAR (OR 0.83; 95% CI: 0.76-0.91); and LER (OR 0.91; 95% CI: 0.87-0.94).
Prolonged opioid use is common following major vascular surgery, occurring in over 10% of patients undergoing either open or endovascular aneurysm repair and over 25% of patients undergoing open LER. Prior opioid use is the strongest predictor for prolonged use, while the occurrence of postoperative complications is associated with a slight increased risk of prolonged use in patients undergoing LER. These patient populations should be targeted for multimodal methods of opioid reduction following their procedures.
很少有研究关注大血管手术后长期使用阿片类药物的风险,且尚无研究调查重大并发症与长期使用阿片类药物之间的潜在关联。我们分析了一个与处方数据库相关联的基于人群的数据库,以调查大血管手术后长期使用阿片类药物的相关因素。
这项基于人群的队列研究纳入了2013年至2018年期间在加拿大安大略省接受开放性下肢血管重建术(LER)或非破裂性腹主动脉瘤修复术(开放性[AAA]和血管腔内修复术[EVAR])的所有成年人。长期使用阿片类药物的定义为术后6至12个月内开具2张或更多阿片类药物处方。使用修正泊松回归和广义估计方程方法探索长期使用的潜在预测因素,以考虑医生和机构内患者的聚集情况。
本研究共纳入11104例患者,其中5652例接受开放性LER,3285例接受EVAR,2167例接受AAA。LER患者先前使用阿片类药物的比例为35.4%,AAA患者为15.8%,EVAR患者为14.3%。每种手术术后的主要并发症发生率分别为:AAA为59.5%,LER为35.1%,EVAR为21.0%。术后,26.1%的LER患者、13.2%的AAA患者和11.6%的EVAR患者被确定为长期使用阿片类药物。长期使用阿片类药物的最强预测因素是先前使用情况,AAA的比值比(OR)为13.27(95%CI:10.63 - 16.57),EVAR为11.24(95%CI:9.18 - 13.75),LER为4.69(95%CI:4.16 - 5.29)。重大并发症的发生仅与接受LER的患者长期使用阿片类药物有关(OR 1.10;95%CI:1.03 - 1.19),而对接受EVAR的患者有保护作用(OR 0.83;95%CI:0.69 - 0.99),对接受开放性AAA修复的患者无关联(OR 1.11;95%CI:0.95 - 1.29)。年龄较大也具有保护作用,每增加10岁,长期使用阿片类药物的比例降低:AAA(OR 0.87;95%CI:0.77 - 0.99);EVAR(OR 0.83;95%CI:0.76 - 0.91);LER(OR 0.91;95%CI:0.87 - 0.94)。
大血管手术后长期使用阿片类药物很常见,在接受开放性或血管腔内动脉瘤修复术的患者中超过10%出现,在接受开放性LER的患者中超过25%出现。先前使用阿片类药物是长期使用的最强预测因素,而术后并发症的发生与接受LER的患者长期使用风险略有增加有关。这些患者群体应在术后采用多模式方法减少阿片类药物使用。